Drug intelligence / Profile preview

Peitu Qingre Jieyu

Development stage: Unknown
Lead developer: Shanghai Baoshan Hospital of Integrated Chinese and Western Medicine
Modality: Small Molecules
Administration: Oral

Overview

Peitu Qingre Jieyu is a Traditional Chinese Medicine (TCM) formula, administered as granules, currently under clinical investigation for its therapeutic potential in ophthalmological conditions. Specifically, it is being studied for the treatment of severe nonproliferative diabetic retinopathy, proliferative diabetic retinopathy, and diabetic macular edema. The drug is being developed by Shanghai Baoshan District Integrated Traditional Chinese and Western Medicine Hospital and Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine.

Other names: Peitu Qingre Jieyu formula granules培土清热解瘀方颗粒剂

Beyond the preview

Go deeper on Peitu Qingre Jieyu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peitu Qingre Jieyu.

Explore the full profile